---
figid: PMC12113536__metabolites-15-00304-g003
figtitle: Mevalonate pathway, highlighting the inhibition of HMG-CoA reductase using
  simvastatin
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC12113536
filename: metabolites-15-00304-g003.jpg
figlink: /pmc/articles/PMC12113536/figure/F3/
number: F3
caption: The mevalonate pathway, highlighting the inhibition of HMG-CoA reductase
  using simvastatin. ‘HMG-CoA’ denotes β-Hydroxy β-methylglutaryl-CoA. Figure created
  using BioRender.com
papertitle: 'SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid
  Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and
  Ongoing Clinical Trials'
reftext: Abdul L. Shakerdi, et al. Metabolites. 2025 May;15(5).
year: '2025'
doi: 10.3390/metabo15050304
journal_title: Metabolites
journal_nlm_ta: Metabolites
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: rhabdoid tumours | SMARCB1 deficiency | hallmarks of cancer | energy metabolism
  | targeted therapy
automl_pathway: 0.9363192
figid_alias: PMC12113536__F3
figtype: Figure
redirect_from: /figures/PMC12113536__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC12113536__metabolites-15-00304-g003.html
  '@type': Dataset
  description: The mevalonate pathway, highlighting the inhibition of HMG-CoA reductase
    using simvastatin. ‘HMG-CoA’ denotes β-Hydroxy β-methylglutaryl-CoA. Figure created
    using BioRender.com
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Acetyl-CoA
  - Simvastatin
  - Cholesterol
---
